This pharmaceutical stock will be suspended from trading on the 20th due to the acquisition of assets! There have been many unsuccessful reorganizations

【Pharmaceutical Network Pharmaceutical Stock Market】Recently, Fengyuan Pharmaceutical issued an announcement that the company is planning to issue shares to purchase assets and raise supporting funds
.
The company intends to acquire no less than 51% of the equity
of Anhui Tigermed Biotechnology Co.
, Ltd.
The counterparties of this transaction are shareholders of Anhui Tigermed Biotechnology Co.
, Ltd.

, the controlling shareholder of the target company.
According to the data, Fengyuan Pharmaceutical is a listed company in the pharmaceutical sector of Fengyuan Group, and the company's main business mainly includes four major sectors
: preparations, APIs, health care and commercial logistics 。 Among them, while focusing on chemical preparations, the preparation sector actively cooperates with various key scientific research institutions and universities to develop a new generation of biological innovative drugs and actively transform and develop into biological preparations; In terms of APIs, through the upgrading of production equipment and high-tech investment, it has increased the market share of paracetamol, cefpirome, ceftriaxone, cefminol and DC series APIs, and has a number of API reserve projects; In the field of health care, it will accelerate the promotion of the Fengyuan Pharmacy Thousand Store Plan, establish an ecological drug retail service platform integrating physical pharmacies and pharmaceutical e-commerce, continue to promote the integration of medical and elderly care and healthy elderly care through mergers, reorganizations, acquisitions, etc.
, and actively implement hospital mergers and acquisitions cooperation projects; The commercial logistics business will set up drug distribution branches in various cities in Anhui Province to establish a complete drug distribution network
.
Anhui Tigermed Biotechnology Co.
, Ltd.
is a holding subsidiary
of Fengyuan Group.
The company's main products are VC raw powder, VC phosphate, coated VC, liquid VC, VE, biotin, cologne, acidulant, of which VC phosphate has an important position
in the global market 。 Tigermed unswervingly follows the corporate philosophy of "reproducing green life and caring for human health" of Fengyuan Group, and takes "openness, justice and fairness" to the three publics; The four strict "strict management, strict and fair, strict and affectionate, strict and trustworthy" and five to "people-oriented, lead by example, to reason to persuade people, to convince people with technology, to serve people with morality" management principles, adhere to the market-oriented, customer-oriented service principle, always take scientific and technological innovation as the driving force of enterprise development, take talent strategy as the basis of enterprise development, constantly seek the development and growth of enterprises, and make greater contributions
to promoting the vigorous development of China's feed industry and human health.
Up to now, Anhui Tigermed Biotechnology Co.
, Ltd.
holds 89.
55% of the equity
of the target company.
Fengyuan Pharmaceutical's shares have been suspended from trading since December 20, and it is expected to disclose the transaction plan within no more than 10 trading days, that is, to disclose relevant information
in accordance with the requirements of the Guidelines for the Content and Format of Information Disclosure of Companies Offering Securities to the Public No.
26 - Major Asset Restructuring of Listed Companies before January 4, 2023 。 It is worth mentioning that Fengyuan Pharmaceutical has initiated major asset restructuring many times before, first twice failed to restructure PushPharmaceutical, and then shifted the acquisition target to Anhui Pharmaceutical, and in November 2017, the company announced that it would terminate the planning to acquire 100% of the equity of Anhui Pharmaceutical, and promised not to plan for major asset restructuring matters for at least 2 months from the date of this announcement
.
Some analysts believe that behind the frequent restructuring of pharmaceutical companies, it may be related to
the lack of performance growth of the company.
However, from the company's third quarter report in 2022, the performance has been better
than before.
According to the third quarter report of Fengyuan Pharmaceutical in 2022, the company's main revenue was 2.
865 billion yuan, an increase of 9.
39% over the same period last year; net profit attributable to owners was RMB126 million, up 40.
22% year-on-year; Deducted non-net profit of 87.
3476 million yuan, up 41.
02% from the same period last year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 968 million yuan, a year-on-year increase of 10.
47%; The net profit attributable to the parent in a single quarter was 37.
9983 million yuan, a year-on-year increase of 42.
69%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.